Clinical trial
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma: A Randomized Multicenter Prospective Phase II Study
NCT04157478 is registered in ClinicalTrials.gov with People's Hospital of Guangxi Zhuang Autonomous Region as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma: A Randomized Multicenter Prospective Phase II Study
- Lead sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2020
- Completion date
- December 31, 2024
- Enrollment
- 464 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.